|
Current and Repurposing Medication for SARS-CoV-2 Infection |
|---|---|
| รหัสดีโอไอ | |
| Creator | Kittiya Jantarathaneewat |
| Title | Current and Repurposing Medication for SARS-CoV-2 Infection |
| Contributor | Korakoch Kangwantas, Nattapong Tidwong |
| Publisher | Thammasat Printing House |
| Publication Year | 2564 |
| Journal Title | Asian Medical Journal and Alternative Medicine |
| Journal Vol. | 21 |
| Journal No. | Supplement 1 |
| Page no. | S91 |
| Keyword | SARS-CoV-2, COVID-19, Repurposing agents, Antiviral, Remdesivir |
| URL Website | http://asianmedjam.com/ |
| Website title | asianmedjam |
| ISSN | 2730-3578 |
| Abstract | In the crisis of COVID-19 pandemic, there is no specific agent to treat SARS-CoV-2 infection. Repurposing medication can be an alternative agent. Remdesivir is the first antiviral drug that has been approved for COVID-19 treatment whereas lopinavir/ritonavir and hydroxychloroquine, which was early used in SARS-CoV-2 widespread, are against by well-known guidelines due to lack of efficacy and potentialtoxicity. Corticosteroids are an essential supportive care in COVID-19 patient with severe disease to reduce lung inflammation. Favipiravir may have a potential benefit for COVID-19 patient, but the data is still uncertain. Ivermectin, an antihelmintic agent, may be used against SARS-CoV-2 but further studies are needed. Immunomodulatory such as tocilizumab in combination with dexamethasone can be used for reducing inflammatory storm during severe COVID-19. Baricitinib is considered as an alternative agent for patients with COVID-19. Repurposing drugs with possible mechanism against SARS-CoV-2 are essential key to combat with SARS-CoV-2 during the specific medications under investigation. |
